Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $445.33 in the latest trading session, marking a -0.86% move from the prior day.
Moderna (MRNA) Files for Full Approval of COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) seeks full approval for its COVID-19 vaccine, mRNA-1273, in adults with initiation of rolling submission of a BLA. The company also boosts manufacturing capacity for the vaccine.
LabCorp (LH) New Study Looks at COVID-19 Antibody Longevity
by Zacks Equity Research
LabCorp (LH) claims this to be the largest known COVID-related study in terms of specimen volume.
Thermo Fisher's (TMO) New Alliance Boosts Electron Microscopy
by Zacks Equity Research
This instrument by Thermo Fisher (TMO) is set to play a vital role in developing advanced solar cells, transport alloys, battery materials, low-energy electronics, catalysts and biodegradable polymers.
Thermo Fisher (TMO) to Boost Cell Therapies With UCSF Deal
by Zacks Equity Research
Thermo Fisher's (TMO) collaboration with UCSF will enable end-to-end solution to accelerate cell therapy development and manufacturing with new facility.
The Zacks Analyst Blog Highlights: UnitedHealth, PayPal, NextEra Energy, Thermo Fisher Scientific and Anheuser-Busch InBev
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, PayPal, NextEra Energy, Thermo Fisher Scientific and Anheuser-Busch InBev
Top Stock Reports for UnitedHealth, PayPal & NextEra
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), PayPal (PYPL), and NextEra (NEE).
Healthcare ETFs on Radar As Q1 Earnings Unfold
by Sweta Killa
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.
Medical Products' Apr 29 Earnings Roster: TMO, BAX & More
by Trina Mukherjee
The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
Is a Surprise Coming for Thermo Fisher (TMO) This Earnings Season?
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at Diagnostics segment.
Thermo Fisher (TMO) to Report Q1 Earnings: WIll It Beat?
by Zacks Equity Research
Fewer hospital visits on growing new cases might have once again impacted the level of routine diagnostics testing activity for Thermo Fisher (TMO) in Q1.
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Thermo Fisher (TMO) to Expand in Pharma Service With PPD Buyout
by Zacks Equity Research
Thermo Fisher's (TMO) $17.4-billion acquisition deal will offer the company meaningful cost and revenue synergies.
MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth
by Urmimala Biswas
While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.
5 ETFs to Make the Most of Thermo Fisher Deal to Buy PPD
by Sweta Killa
Thermo Fisher Scientific (TMO) has agreed to buy the healthcare testing company PPD Inc. (PPD) for $17.4 billion in cash.
Company News for Apr 16, 2021
by Zacks Equity Research
Companies in the news are: BLK, PEP, DELL, TMO
What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.
Thermo Fisher (TMO) Gets EUA for Amplitude/TaqPath COVID-19 Kit
by Zacks Equity Research
Thermo Fisher's (TMO) Amplitude Solution is likely to allow clinical and public health laboratories to process up to 8,000 samples in a single day with the help of minimum workforce.
Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On
by Zacks Equity Research
In diagnostics and healthcare, Thermo Fisher (TMO) is experiencing high demand for COVID-19 testing and manages to record 200% growth.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher, T-Mobile, Medtronic and Square
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher, T-Mobile, Medtronic and Square